FA complementation group LGenealiases: FAAP43 · PHF9 · POG
Q-omics provides the consensus-scored FANCL profile across patient tissues and cancer cell-line models. FANCL expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FANCL is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, FANCL RNA expression shows 20,457 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where FANCL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FANCL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FANCL survival associations across molecular data types. FANCL RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FANCL RNA expression–survival associations across cancer types. High FANCL expression shows unfavorable associations in LIHC, KICH, LUAD, LGG, KIRP and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FANCL RNA expression.
This table summarizes FANCL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FANCL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FANCL shows higher tumor expression in KIRC, BLCA, COAD, STAD, HNSC and LIHC. The KIRC box plot shows higher FANCL RNA expression in tumor versus normal tissue (log2 FC = +0.704, t-test p < 0.001).
This table shows molecular features associated with FANCL in patient tissues and cancer cell lines. In patient samples, FANCL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FANCL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
